An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) will release its first-quarter 2024 financial results on May 7, 2024. The management will host a live webcast to review the financial and operating results at 8 a.m. Eastern Time. Participants can access the webcast on the company's Investor Relations section of the website.
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) pubblicherà i risultati finanziari del primo trimestre del 2024 il 7 maggio 2024. La direzione ospiterà un webcast dal vivo per discutere i risultati finanziari e operativi alle 8:00, ora dell'Est. I partecipanti possono accedere al webcast nella sezione Relazioni con gli Investitori del sito web dell'azienda.
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) publicará sus resultados financieros del primer trimestre de 2024 el 7 de mayo de 2024. La gerencia organizará una transmisión en vivo para revisar los resultados financieros y operativos a las 8 a.m. hora del Este. Los participantes pueden acceder a la webcast en la sección de Relaciones con Inversores del sitio web de la compañía.
마드리갈 파마슈티컬스, Inc. (나스닥: MDGL)는 2024년 5월 7일에 2024년도 1분기 재무 결과를 발표할 예정입니다. 경영진은 동부 표준시 오전 8시에 재무 및 운영 결과를 검토하기 위한 생방송 웹캐스트를 개최할 것입니다. 참가자는 회사의 투자자 관계 섹션 웹사이트에서 웹캐스트에 접속할 수 있습니다.
Madrigal Pharmaceuticals, Inc. (Nasdaq : MDGL) publiera ses résultats financiers du premier trimestre 2024 le 7 mai 2024. La direction organisera une webdiffusion en direct pour examiner les résultats financiers et opérationnels à 8 heures, heure de l'Est. Les participants peuvent accéder à la webdiffusion dans la section Relations avec les investisseurs du site web de la société.
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) wird am 7. Mai 2024 seine Finanzergebnisse für das erste Quartal 2024 veröffentlichen. Das Management wird um 8 Uhr Eastern Time einen Live-Webcast veranstalten, um die finanziellen und betrieblichen Ergebnisse zu überprüfen. Teilnehmer können den Webcast im Investor Relations-Bereich der Unternehmenswebsite aufrufen.
Positive
None.
Negative
None.
CONSHOHOCKEN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2024 financial results on Tuesday, May 7, 2024, prior to the open of the U.S. financial markets.
Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.
The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.
The webcast will be available approximately two hours after the live webcast.
About Madrigal Pharmaceuticals Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.
Investor Contact Tina Ventura, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com
